P
Patrick Y. Wen
Researcher at Harvard University
Publications - 938
Citations - 64584
Patrick Y. Wen is an academic researcher from Harvard University. The author has contributed to research in topics: Glioma & Medicine. The author has an hindex of 109, co-authored 838 publications receiving 52845 citations. Previous affiliations of Patrick Y. Wen include University of Texas MD Anderson Cancer Center & Nanjing Medical University.
Papers
More filters
Journal ArticleDOI
Malignant Gliomas in Adults
Patrick Y. Wen,Santosh Kesari +1 more
TL;DR: The authors found that approximately 5% of patients with malignant gliomas have a family history of glioma and most of these familial cases are associated with rare genetic syndromes, such as neurofibromatosis types 1 and 2, the Li−Fraumeni syndrome (germ-line p53 mutations associated with an increased risk of several cancers), and Turcot's syndrome (intestinal polyposis and brain tumors).
Journal ArticleDOI
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen,David R. Macdonald,David A. Reardon,Timothy F. Cloughesy,A. Gregory Sorensen,Evanthia Galanis,John DeGroot,Wolfgang Wick,Mark R. Gilbert,Andrew B. Lassman,Christina Tsien,Tom Mikkelsen,Eric T. Wong,Marc C. Chamberlain,Roger Stupp,Kathleen R. Lamborn,Michael A. Vogelbaum,Martin J. van den Bent,Susan M. Chang +18 more
TL;DR: The recognition that contrast enhancement is nonspecific and may not always be a true surrogate of tumor response and the need to account for the nonenhancing component of the tumor mandate that new criteria be developed and validated to permit accurate assessment of the efficacy of novel therapies.
Journal ArticleDOI
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman,Michael D. Prados,Patrick Y. Wen,Tom Mikkelsen,David Schiff,Lauren E. Abrey,W. K. Alfred Yung,Nina Paleologos,Martin K. Nicholas,Randy L. Jensen,James J. Vredenburgh,Jane Huang,Maoxia Zheng,Timothy F. Cloughesy +13 more
TL;DR: Bvacizumab, alone or in combination with irinotecan, was well tolerated and active in recurrent glioblastoma in a phase II, multicenter, open-label, noncomparative trial.
Journal ArticleDOI
AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients
Tracy T. Batchelor,A. Gregory Sorensen,A. Gregory Sorensen,Emmanuelle di Tomaso,Wei Ting Zhang,Wei Ting Zhang,Dan G. Duda,Kenneth S. Cohen,Kevin R. Kozak,Daniel P. Cahill,Poe Jou Chen,Poe Jou Chen,Mingwang Zhu,Mingwang Zhu,Marek Ancukiewicz,Maciej M. Mrugala,Scott R. Plotkin,Jan Drappatz,David N. Louis,Percy Ivy,David T. Scadden,Thomas Benner,Jay S. Loeffler,Patrick Y. Wen,Rakesh K. Jain +24 more
TL;DR: This study provides insight into different mechanisms of action of this class of drugs in recurrent glioblastoma patients and suggests that the timing of combination therapy may be critical for optimizing activity against this tumor.
Journal ArticleDOI
Exciting New Advances in Neuro-Oncology The Avenue to a Cure for Malignant Glioma
Erwin G. Van Meir,Constantinos G. Hadjipanayis,Andrew D. Norden,Hui-Kuo G. Shu,Patrick Y. Wen,Jeffrey J. Olson +5 more
TL;DR: There is definite hope that by 2020, new cocktails of drugs will be available to target the key molecular pathways involved in gliomas and reduce their mortality and morbidity, a positive development for patients, their families, and medical professionals alike.